Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
24.75
+0.65 (2.70%)
Feb 27, 2026, 4:00 PM EST - Market closed
AAPG Employees
Ascentage Pharma Group International had 605 employees as of June 30, 2025. The number of employees increased by 38 or 6.70% since the number was reported on December 31, 2024.
Employees
605
Change
38
Growth
6.70%
Revenue / Employee
$90,123
Profits / Employee
-$267,461
Market Cap
2.21B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,294 |
| Telix Pharmaceuticals | 1,184 |
| Galapagos NV | 558 |
| Nuvation Bio | 291 |
| Immunome | 168 |
| Stoke Therapeutics | 128 |
| Mesoblast | 81 |
AAPG News
- 16 days ago - Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 23 days ago - Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 6 weeks ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga
- 2 months ago - ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP - GlobeNewsWire
- 2 months ago - ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% - GlobeNewsWire